T1	Participants 125 158	premenopausal early breast cancer
T2	Participants 182 240	Austrian Breast and Colorectal Cancer Study Group Trial 12
T3	Participants 525 753	premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy
T4	Participants 759 772	1803 patients
